Medicare Reprices the Hospital Outpatient Premium Site by Site

Medicare Reprices the Hospital Outpatient Premium by Service Family, and From 2028 Site by Site

The hospital outpatient premium is being withdrawn one service family at a time: clinic visits in 2019, drug administration in 2026, imaging without contrast proposed for 2027. From 2028 every off-campus department bills under its own identifier. Exposed: health systems, practice acquirers, imaging operators, ambulatory surgery investors.

Produced using Shaping Tomorrow’s six-stage process for converting external change into decision-ready intelligence.
Scanned and filtered by AI. Stress-tested and judged by humans.

The CY 2027 outpatient rule is being argued as a 340B fight, and the $4.55 billion drug reduction is the number everyone has quoted. The durable change sits elsewhere. Medicare has been removing the payment premium attached to hospital outpatient departments one service family at a time: clinic visits in 2019, drug administration in 2026, imaging without contrast proposed for 2027, with the agency asking which families should come next. Congress has supplied the enforcement layer, requiring every off-campus department to bill under its own identifier from 2028. What health systems bought when they acquired practices is being itemised first, and repriced after.

Signal Identification

A regulatory pivot with a published cadence rather than a single cut. Each annual rule names one more group of codes and pays them at the physician-office rate, while the inpatient-only list empties and the ambulatory surgery list fills. The exposure is not the size of any one reduction. It is that the sequence is announced in advance and the agency has invited comment on which families to take next.

Time horizon: 1-5 years (comments closed 31 August 2026 and a final rule is expected late in 2026; imaging repricing from January 2027; separate identifiers for off-campus departments from January 2028; inpatient-only list due to be gone by January 2029)

Plausibility band: High

Geographic / Jurisdictional Scope: Primary: the United States, where Medicare rates set the reference point for commercial contracts. Spillover: owners and lenders outside the US whose valuations rest on US outpatient tariffs, and global imaging and device vendors.

PrimaryUnited States

SpilloverNon-US owners of US assetsGlobal device vendors

Sectors exposed:

Hospitals and health systemsAmbulatory surgery centres and investorsPhysician practice groups and their acquirersDiagnostic imaging operatorsMedical device vendorsHealthcare real estate and creditPrivate equity healthcare portfolios

What's Changing

CMS issued the CY 2027 proposed rule on 2 July 2026, the third application of a single method. Clinic visits went to the physician-office rate in 2019, drug administration in the CY 2026 final rule, and imaging without contrast is now proposed, worth about $260 million of Part B reductions in year one (Centers for Medicare & Medicaid Services, 02/07/2026). The purpose is stated without hedging: such differentials “may encourage greater consolidation within the healthcare system by motivating hospitals to acquire independent physician practices to increase their Medicare prices” (Centers for Medicare & Medicaid Services, 02/07/2026).

The estate moves with it. The inpatient-only list held about 1,428 services; 285 came off in 2026, 637 are proposed for 2027, and the list is due to disappear on 1 January 2029, while roughly 618 surgical codes join the ambulatory surgery centre list (Applied Policy, 04/07/2026). The 340B change takes the headlines, at average sales price minus 33.4% after a survey answered by about 41% of eligible hospitals, which safety-net hospitals read as a total cut of 39.4% from the default rate (America's Essential Hospitals, 07/07/2026).

The accounting is also being taken down to the site. Under section 6225 of the Consolidated Appropriations Act, 2026, each off-campus department bills under its own National Provider Identifier from 1 January 2028, behind a provider-based attestation (K&L Gates, 03/08/2026). CMS asked whether to use the same authority on more services; the American Action Forum named five further families and put the saving above $1.6 billion in nine months (American Action Forum, 27/08/2026).

One method, applied to one service family a year

Sources: Centers for Medicare and Medicaid Services, 2 July 2026; Applied Policy, 4 July 2026; K&L Gates, 3 August 2026; American Action Forum, 27 August 2026.

Disruption Pathway

Stage one is the final rule, expected late in 2026 after comments closed on 31 August (K&L Gates, 03/08/2026). Stage two runs through 2027 and 2028: the identifier requirement makes each off-campus department separately visible, and the provider-based attestation turns a billing convention into a compliance representation that can be examined. Stage three is 2029, when the inpatient-only list is due to be gone and the question for each procedure stops being whether it may be done outside the hospital and becomes which outpatient setting is cheapest.

Stress concentrates in three places. Practices bought at multiples built on converting physician-office billing into outpatient-department billing, a conversion now being unwound code by code; the American Action Forum puts the gap at about 320% for a level 1 skin procedure (American Action Forum, 27/08/2026). The 340B hospitals, which take the drug reduction and an accelerated recoupment at 3% of the conversion factor together (America's Essential Hospitals, 07/07/2026). And imaging and surgical capacity sited on hospital campuses against the old tariff. Two adaptations follow. Capital moves toward ambulatory surgery centres, which gain codes while the hospital rate falls. And provider-based status becomes a governance item rather than a billing detail, because a department that cannot evidence compliance loses the billing right, not just the margin.

Why This Matters Now

This lands on health system finance chiefs holding practice acquisitions priced on a billing conversion, on the investors and ambulatory surgery operators reading the same rule as an opening, on imaging businesses, and on the analysts who rate hospital debt against outpatient margins. The assumption to revise is that site-neutral policy is an annual rate risk to be lobbied down. Taken together, the documents describe a sequence with a stated direction and an enforcement mechanism dated 2028. Boards should establish what share of outpatient revenue sits in families CMS has already repriced or opened for comment, which off-campus departments could evidence provider-based compliance today, and what a practice bought in 2022 is worth once its billing converts back. Those answers take longer to assemble than a comment cycle.

Decision-action posture for this signal: Prepare — the cadence and the 2028 identifier requirement are established, but the imaging step is still a proposal and the final rule is due late in 2026, so the work is to model exposure by service family and test provider-based compliance rather than to restructure against a rule that is not yet final.

Counter-Argument

The strongest objection is that almost no money leaves the system. The 340B change is budget neutral by statute, so CMS must raise payments for non-drug services by the same amount, which is why 340B Health argues the policy “instead uses that revenue to pay more to non-safety net providers” (Fierce Healthcare, 06/07/2026), and why hospital groups read the imaging step as another cut to payments they need to stay open. The saving is also small against a base of roughly $110.9 billion in projected CY 2027 OPPS payments (Applied Policy, 04/07/2026).

Both readings are right about this year and miss the instrument. Budget neutrality redistributes between hospitals; it does not restore the differential between an outpatient department and a physician office, which is what priced the acquisitions. And a small first-year figure is what a sequence looks like at the start: clinic visits were small in 2019 too.

Implications

This is durable rather than transitional, because the instrument is a method rather than a rate. CMS has now used the same statutory authority three times and asked which services should be next (Centers for Medicare & Medicaid Services, 02/07/2026), and Congress has supplied per-site identification from 2028. On the available evidence the direction is one-way, and the inflection window runs from the final rule late in 2026 to the end of the inpatient-only list in 2029. Ambulatory surgery operators, imaging chains and independent practices gain. Health systems carrying acquisition goodwill against converted billing, 340B disproportionate share hospitals, and departments that cannot evidence provider-based status carry the exposure.

Early Indicators to Monitor

The final CY 2027 rule confirming the physician-office rate for imaging without contrast, and naming any further service families.
A comment cycle opening on skin procedures, nerve injections or minor procedures, the families nominated in the comment round.
Sub-regulatory guidance on the off-campus provider-based attestation due from January 2028.
Health systems disclosing impairment or shortened useful life on physician practice intangibles in 2027 filings.
Ambulatory surgery centre transaction multiples rising as newly covered surgical codes start billing.

Disconfirming Signals

The final rule dropping the imaging proposal after the August comment round.
Congress delaying or repealing the separate identifier requirement before January 2028.
CMS pausing the inpatient-only list phase-out rather than completing it by 2029.
Hospital outpatient surgical volumes holding steady, with no migration to ambulatory surgery centres.
Commercial payers continuing to pay outpatient-department rates for the repriced families, leaving system economics intact.

Strategic Questions

What share of our outpatient revenue sits in families CMS has already repriced or opened for comment?
Which off-campus departments could evidence provider-based compliance under attestation today?
Do we buy ambulatory surgery capacity now, or wait for the final rule late in 2026?

Keywords

Site-neutral payment; hospital outpatient department; OPPS; 340B Drug Pricing Program; inpatient-only list; ambulatory surgery centres; provider-based status; National Provider Identifier; vertical integration; physician practice acquisition; Medicare Part B; imaging without contrast

Bibliography

Source tiers: Tier 1, governments, regulators and intergovernmental bodies. Tier 2, think-tanks, academic institutes, major consultancies and quality data providers. Tier 3, quality journalism and specialist trade press. Tier 4, vendor, company and practitioner sources, used only as directional corroboration.

Tier 1 Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P). Centers for Medicare & Medicaid Services (02/07/2026).
Tier 1 CMS Acts to Strengthen Care Quality, Cut Drug Costs, and Slash Out-of-Pocket Expenses for Medicare Beneficiaries. Centers for Medicare & Medicaid Services (02/07/2026).
Tier 2 CMS Proposes Major CY 2027 OPPS/ASC Changes Targeting 340B Payments, Site-Neutral Policy, IPO List Phase-Out, and ASC Expansion. Applied Policy (04/07/2026).
Tier 2 Comments to CMS on CY 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule. American Action Forum (27/08/2026).
Tier 3 CMS' 2027 outpatient pay proposal brings 340B, site-neutral changes, to hospitals' dismay. Fierce Healthcare (06/07/2026).
Tier 3 CMS CY 2027 OPPS/ASC Proposed Rule: Key Payment and Policy Changes for Hospitals, Health Systems, and ASCs. K&L Gates (03/08/2026).
Tier 4 CMS Issues CY 2027 OPPS Proposed Rule. America's Essential Hospitals (07/07/2026).